Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New One-Minute COVID-19 Test Detects Antibodies from Single Drop of Blood

By LabMedica International staff writers
Posted on 30 May 2020
A one-minute test for antibodies to SARS-CoV-2 is currently being developed based on an innovative testing technology that detects antibodies within one minute from a single drop of blood.

The test is being developed on bioLytical Laboratories Inc.’s (Richmond, BC, Canada) proprietary INSTI platform. More...
bioLytical will receive advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop the one-minute test for antibodies to SARS-CoV-2.

INSTI is made in Canada and known for its fast, easy-to-use, and accurate serological tests. As an antibody test, an INSTI test for SARS-CoV-2 can be an important part of the testing strategy in Canada and around the world. By detecting antibodies to COVID-19 in a single drop of blood, INSTI does not require additional materials such as swabs. Along with the test device, all materials required to perform the test are provided together in one small pouch; leading this testing platform to become known as “a lab in a pouch.”

The INSTI SARS-CoV-2 test development project is funded by NRC IRAP and aims to accelerate research and development for solutions to address COVID-19 related gaps and challenges identified by health experts.

Related Links:
bioLytical Laboratories Inc.


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Online QC Software
Acusera 24•7
Pipette Calibration System
Artel PCS®
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Molecular Diagnostics

view channel
Image: The Co-Dx PCR platform combines real-time PCR quality with a lower-cost instrument and consumable model to facilitate deployment near the patient (Photo courtesy of Co-Diagnostics, Inc.)

Point-of-Care Multiplex PCR Test Submitted to FDA for Flu A/B and RSV Detection

Co-Diagnostics, Inc. (Co-Dx; Salt Lake City, UT, USA) has submitted the Co-Dx PCR Flu A/B & RSV upper respiratory multiplex test for use on the Co-Dx PCR Pro instrument through a Dual 510(k) premarket... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.